by Singapore Trader Reports
A well fact amongst the trading community is that 90 percent of investors lose money in futures and Forex tradin! This leaves 10%, which is then broken down to 4-6 percent break even and only 4-6 percent make money.

What Group Are YOU in?

Given the high numbers of clients that are unsuccessful, it is all the more important for investors to approach futures and forex trading in the right manner. So we have put together some rules that hopefully help you become a more successful trader.

Secret 1: Trade with Money you can afford to Lose

Now that you have decided to get involved in trading, sit down and asses how much money am I going to trade, investor, speculate on the market with. I understand that this is trading and therefore there is the chance that I can lose my money.

Secret 2: It’s Not how many trades: …

Hologic, Inc. (HOLX) is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic’s core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. The company, in June, announced the acquisition of Third Wave Technologies, which developed and marketed molecular diagnostic reagents for a wide variety of DNA and RNA analysis applications based on its proprietary Invader® chemistry.

Hologic recently announced it is the first diagnostic medical device manufacturer to receive U.S. Food and Drug Administration clearance to incorporate the World Health Organization (WHO) FRAX™ 10-year fracture risk calculator into its bone densitometer systems. The WHO Collaborating Centre for Metabolic Bone Diseases, located at the University of Sheffield Medical School, U.K., developed FRAX as a tool to help healthcare providers identify and proactively treat patients with a high risk of bone

...

Rexahn Pharmaceuticals, Inc. (AMEX: RNN), a leader in innovative therapeutics for life-threatening and life-debilitating diseases, recently announced that the company has received FDA approval to begin Phase II trials for Serdaxin™, for the treatment of major depressive disorders. Serdaxin is being developed as an orally administered, extended-release tablet for the treatment of depression and anxiety.

According to the World Health Organization, major depressive disorder is the leading cause of disability in the United States for ages 15 to 44. There are 154 million cases of depression reported worldwide each year, and this condition is nearly twice as prevalent in women as in men. Major depressive disorder is expected to become the second-leading cause of disability worldwide by the year 2020.

Serdaxin is a dual enhancer of serotonin and dopamine neurotransmitters. In preclinical studies, Serdaxin was shown to significantly improve an individual’s negative mood state and the loss of positive mood state,

...

Healthways, Inc. (HWAY) is a provider of specialized, comprehensive health and care support(SM) solutions to help millions of people maintain or improve their health and, as a result, reduce overall healthcare costs. Healthways’ solutions are designed to help healthy individuals stay healthy, mitigate and slow the progression of diseases associated with family or lifestyle risk factors, and promote the best possible health for those already affected by disease. Healthways also provides a national, fully accredited, complementary and alternative Health Provider Network, offering convenient access to individuals who seek health services outside of, and in conjunction with, the traditional healthcare system.

Research released last Friday from the Gallup-Healthways Well-Being Index reveals that the downward trend in overall well-being appears to be cushioned when workers experience a positive work environment; one where they get to use their strengths, and where their supervisors create a trusting environment. In the first six

...

The World Health Organization says that 25% of Chinese are now overweight and it blames the growing popularity of western foods in China.I don't believe those numbers one bit. I've seen a fair amount of overweight people in Japan and India....but very few in China. I do agree that western foods are becoming very popular in China. Especially KFC and Pizza Hut.

Researchers will be the first to adapt to anything that could further their work or make it easier. Sitting still with current research tool options is just not an option. Providing researchers with more efficient ways to reference their work, whether scientific, business or administrative, offers a solid path to profit. Some may have thought Google’s search engine was a breakthrough; they have not yet begun to see what the next best thing is now.

Collexis Holdings Inc., a knowledge search engine software company, offers a unique product oriented toward delivering more specific search results to researchers in all fields. Its “fingerprint” technology essentially works to deliver more relevant search articles then a standard search engine quarry. The system is customizable and is currently in use by many prestigious organizations such as the Mayo Clinic, the World Health Organization and several state bar associations.

Although the company’s software product may appear to

...

Viral Genetics Inc. is a biotechnology company with a focus on protein-based therapeutic and diagnostic products with applications in infectious disease, autoimmune conditions, and immunological deficiency. The company and its management team are key players in the fight against HIV/AIDS, infectious disease, and autoimmune deficiency. Viral Genetics has been working since 1995 to find a cure for HIV/AIDS and is based in Azusa, California.

VRAL develops its products based on thymus nuclear protein (TNP), a processed extract of mammalian thymus tissue. It has developed a lead product, VGV-1, which is a suspension of TNP in alum adjuvant for the treatment of HIV infection and AIDS. VGV-1 is currently in the preclinical stage of development in the United States, but outside of the USA it is in later stage development. Viral Genetics believes that VGV-1 represents a significant and unique approach to treating HIV due to the apparently novel mechanism, low toxicity

...